Navigation Links
Medizone International, Inc. Announces Establishment of Canadian Foundation for Global Health
Date:10/30/2008

SAN FRANCISCO, Oct. 30 /PRNewswire-FirstCall/ -- Medizone International, Inc. (Pink Sheets: MZEI) is pleased to announce the formal establishment of a not-for-profit affiliate, the Canadian Foundation for Global Health (CFGH). CFGH was founded under Canadian Federal Law as a not-for-profit Canadian Corporation headquartered in Ottawa, Ontario, Canada. Under the leadership of Dr. Michael E. Shannon, a founding Director and the foundations' newly appointed President, it is anticipated that the foundation will attract a broad spectrum of the most highly qualified scientists, infectious disease specialists and other medical health professionals from diverse fields of interest to serve on its Board of Directors, Science Advisory Board or as Principal Investigators.

Medizone's Board of Directors have adopted a business philosophy of "creating a corporate paradigm in which the corporation's profit follows its' social contribution." The establishment of this foundation fits into that paradigm not only by being positioned to attract the highest quality professionals possible to our research projects, but it is envisioned that as Medizone's products and treatments become ready for market, the foundation may play a vital role as a distribution source for developing countries with varying price breaks depending on the county's needs and the availability of international assistance; we intend to make effort through both the for-profit and the non-profit to make affordable medical solutions as widely available as possible for the people of the planet.

Medizone International, Inc., is a research and development stage company engaged in the development of novel technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to sterilize hospital surgical suites, emergency rooms and intensive care units.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Web site: http://www.medizoneint.com

Investor Relations: 800-953-3350


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
2. Sangui Biotech International, Inc., Reports Sales Decrease, Continued Losses
3. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
4. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
5. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
6. China Yingxia International, Inc. Appoints New Vice President of Finance
7. Chindex International, Inc. Announces Appearances at Upcoming Investor Conferences
8. Sangui BioTech International, Inc. Files Remaining Reports
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
11. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
Breaking Biology Technology:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):